| Erythropoietin claims monitoring policy: implications for clinical practice. | |
| | |
MedLine Citation:
|
PMID: 16613415 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The revised erythropoietin claims monitoring policy that will govern reimbursement by the Centers for Medicare & Medicaid Services for Epoettin alfa and darbepoetin alfa administered to patients on dialysis takes effect on April 1, 2006. The new policy provides several significant improvements that should enhance clinicians' ability to manage anemia rationally. However, several aspects of the new policy are ambiguous and will require further clarification and ongoing evaluation to determine the effect on practice patterns and clinical outcomes. |
| | |
Authors:
|
Tony Messana |
Related Documents
:
|
10267085 - Theory z: a review of management styles and a proposal for change. 19093605 - Deliberate practice theory: relevance, effort, and inherent enjoyment of music practice. 15195275 - Practical application of comfort theory in the perianesthesia setting. 15517095 - The life mission theory vi. a theory for the human character: healing with holistic med... 2328635 - Definitive management of acute pilonidal abscess by loop diathermy excision. 1540755 - The facilitation and evocation of seizures. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Nephrology nursing journal : journal of the American Nephrology Nurses' Association Volume: 33 ISSN: 1526-744X ISO Abbreviation: Nephrol Nurs J Publication Date: 2006 Mar-Apr |
Date Detail:
|
Created Date: 2006-04-14 Completed Date: 2006-05-16 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100909377 Medline TA: Nephrol Nurs J Country: United States |
Other Details:
|
Languages: eng Pagination: 209-13, 222; quiz 214-5 Citation Subset: N |
Affiliation:
|
St. Joseph Hospital Renal Services, Orange, CA, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anemia
/
blood,
drug therapy*,
etiology Centers for Medicare and Medicaid Services (U.S.) / organization & administration Documentation Drug Costs Drug Utilization Epoetin Alfa / economics* Erythropoietin / analogs & derivatives*, economics Hematinics / economics* Hemoglobins / metabolism Humans Insurance Claim Reporting / standards* Kidney Failure, Chronic / complications Organizational Policy Patient Selection Practice Guidelines as Topic Reimbursement Mechanisms / organization & administration* Renal Dialysis / adverse effects Risk Factors Total Quality Management / organization & administration United States |
| Chemical | |
Reg. No./Substance:
|
0/Hematinics; 0/Hemoglobins; 11096-26-7/Erythropoietin; 113427-24-0/Epoetin Alfa; 209810-58-2/darbepoetin alfa |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: How a dedicated vascular access center can promote increased use of fistulas.
Next Document: Peritoneal dialysis as the treatment of choice for pediatric patients. CAPD is the best modality for...